Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| SPHL | Springview | $7.43 | -$9.98 | -57.32% | 4M | $203M | $1.92$62.40 |
| ANPA | Hong Kong Prosperous Sheep | $99.66 | -$58.23 | -36.88% | 120.9K | $2.0B | $2.80$180.64 |
| MLEC | Moolec Science | $5.05 | -$2.65 | -34.42% | 586.7K | $5.6M | $3.08$157.05 |
| RAYA | Erayak Power Solution Group | $2.77 | -$1.16 | -29.52% | 530.4K | $3.5M | $2.63$737.00 |
| PAVM | PAVmed | $6.58 | -$2.17 | -24.80% | 100.5K | $9.3M | $6.00$26.85 |
| SMCZ | Tidal Trust II - Defiance Daily Target 2x Short Smci ETF | $42.75 | -$12.42 | -22.51% | 637.3K | - | $19.85$225.57 |
| AHMA | Ambitions Enterprise Management L.l.c | $23.31 | -$6.07 | -20.66% | 433.6K | $867M | $4.00$31.07 |
| MFI | mF International | $14.11 | -$2.89 | -17.00% | 27.8K | $28M | $4.08$60.73 |
| MTEX | Mannatech | $7.61 | -$1.52 | -16.67% | 57.2K | $17M | $6.90$16.49 |
| ACCL | Acco Group | $2.50 | -$0.49 | -16.39% | 24.3M | $42M | $2.10$5.00 |
Related Articles
Featured Article
1 Small-Cap Stock I'd Buy Before GLBE in 2026
Marc Guberti|Jan 8, 2026
Global-E Online is a small company trying to carve out a niche in the competitive e-commerce space, while AXT is a small semiconductor player that already has a lead in an emerging opportunity.
3 Top Stocks Worth Buying for the Long Term in 2023
Michael Byrne|Dec 30, 2022
Opportunities abound as investors close the book on 2022 and turn to 2023.
This Former SPAC Beat the Market in 2022. Is It a Buy for 2023?
Michael Byrne|Dec 23, 2022
This 112-year-old company is growing like it's the next hot start-up.
Advertisement
What's the Outlook for Arbutus Biopharma?
Keith Speights and Brian Orelli, PhD|Feb 5, 2022
The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.
3 Healthcare Stocks That Rocketed Higher in July
Cory Renauer|Aug 3, 2020
Here's what drove shares of these healthcare stocks through the roof last month.
Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications
Taylor Carmichael|Jul 24, 2020
The ruling means Moderna may have to pay royalties on its mRNA-based vaccines -- including its coronavirus candidate.
